April 05, 2021



### Nifty Outlook

**Derivative Ideas \*\*** 

B/S

**BUY** 

**CASH** 

Instrument

**BHEL** 

Markets started the new financial year on a robust note led by optimism in the global markets. Announcement by US President Joe Biden to invest USD 2.3 trillion in infrastructure boosted sentiments. Initially the benchmark opened gap up but gains fizzled out gradually as the day progressed. However in the second half healthy buying amongst the sectors such as metals, banks, auto supported markets to steadily inch higher. Consequently, the Nifty ended near day's high at 14,867 levels, with gains of 1.2%. The broader markets outperformed and ended higher in range of 1.6-2%. Barring FMCG, all the sectoral indices closed in positive.

Markets are likely to take cues from global peers as stimulus package announcement in the US last night led to renewed buying interest in the global markets. In the near term, positive bias is expected to continue however, rising COVID cases in India would remain a key concern. As Q4 earning season is approaching, Investors focus will shift to earnings announcements and management commentary.

	VWAP (Expiry till date)	Max OI (Call)	Max OI (Put)
NIFTY	14850	15000	14000
News			

- **Maruti Suzuki India** posted total sales of 1,67,014 units in the month of March out of which domestic sales is 1,55,417 units and exports is 11,597 units. For whole FY21, the company posted a total sales of 14,57,861 units, down by 6.7% YoY.
- Alembic Pharmaceuticals announced that its joint venture Aleor Dermaceuticals has
  received final approval from the USFDA for its Abbreviated New Drug Application for
  Nystatin and Triamcinolone Acetonide Cream USP, 100,000 units/gram and 1 mg/gram.
- **Indraprastha Gas** signed a long term gas supply agreement with Delhi Transport Corporation to supply CNG for a period of ten years till December 2030.

48.80

**TARGET** 

54



\*\*Please note that the given technical and derivative recommendations are "valid for taking position" only on recommended date and in the given range.

\*Please note - Stoploss is on closing basis for delivery recommendation and intraday basis for F/O recommendation.

FII & DII	Cash Se	gment	(Rs. in Cr.)	Trade St	ats	
Category	Amt.	MTD	FYTD		NO OF CONTRACTS	TURNOVER IN CR
FII**	-1685	1246	202617	IDXFUTS	398709	37987
• • • • • • • • • • • • • • • • • • • •	1005	1240	202011	IDXOPT	76645897	16170
DII**	2081	5204	-133067	STKFUTS	612224	59750
**Provisio	nal data a	as on 31 <sup>st</sup>	Mar., 2021			

50-50.50



#### **Derivative Ideas**

**BHEL FUTS** added around 7% in open interest as long buildup was seen in it till closing time. Current chart pattern also indicates further up move in its price. We suggest buying BHEL as per below levels.

**Strategy:-** BUY BHEL BETWEEN 50-50.50 STOP LOSS 48.80 TARGET 54.

## Investment Pick - Crompton Greaves Consumer Electricals Ltd.

Scrip	СМР	Recommendation Price	Target	Duration
Crompton Greaves Consumer Electricals Ltd.	393.25	367	479	9-12 Months

Crompton Greaves Consumer Electricals (CGCE) is engaged in manufacturing and marketing of a wide range of consumer products ranging from fans, light sources and luminaires, pumps and household appliances such as geysers, mixer grinders, toasters and irons.

We like CGCE for its strong growth potential, consistent rise in market share in its key segment coupled with healthy dividend pay-out ratio, strong cash flow generation, lean working capital cycle and robust return ratios. We recommend a Buy on the stock with a target price of Rs. 479.

Sun	c Calendar - March 2021 Mon	Tue	Wed	Thu	Fri	Sat
)4	05	06	07	08	09	
,		00		00		10
	Nikkei Markit Manufacturing PMI (Mar)		Cash Reserve Ratio			
			<ul> <li>Interest Rate Decision</li> </ul>			
			Reverse REPO Rate			
			Nikkei Services PMI (Mar)			





Sun	Mon		Tue	Wed	Thu	ı	Fri	Sat	
1	<ul><li>05</li><li>IFL Promoters Ltd.</li></ul>		M. Breweries Ltd. nplex Projects Ltd	. 07	<ul><li>Minal Industries Limit</li><li>SEL Manufacturing Control</li></ul>		09	<ul><li>Minal Industries Limited</li></ul>	d
ACT	Calendar - March 2	2021 (Cas	h Dividend)						
un	Mon		Tue	9	Wed	Th	U	Fri	Sa
	05 Saregama India Ltd. Sbi Life Insurance Compan Shriram Transport Finance	-	Nacl Industries I Shriram City Un		<ul> <li>Edelweiss Financial Services Ltd.</li> </ul>	<ul> <li>Britannia Inc</li> <li>Govind Rubb</li> <li>India Nippon</li> <li>Kama Holdin</li> <li>Premco Glob</li> <li>Rail Vikas Ni</li> </ul>	er Ltd. Electricals Ltd. gs Limited oal Ltd.	<ul><li>Rama Phosphates Ltd.</li><li>Roto Pumps Ltd.</li></ul>	10
	Calendar - March 2			·					
un	Mon	Tu		Wed	Thu		Fr	_	at
	05 06			) (	08	09		10	
	•	SK Internati	onal Export Ltd						
CT	• Calendar - March 2			es)					
	Calendar - March 2 Mon	021 (Buy Tue	Back of Shar Wed		Thu		Fri	Sa	t
	Calendar - March 2 Mon	:021 (Buy	Back of Shar	08 • SIS Ltd		09	Fri		t
un	Calendar - March 2 Mon	021 (Buy Tue 06	Back of Shar Wed	08 • SIS Ltd		09	Fri	Sa	t
un	Calendar - March 2  Mon  05  Calendar - March 2  Mon	021 (Buy Tue 06	Back of Shar Wed 07 solidation of	08 • SIS Ltd Shares) Wed	Thu		Fri Fri	10	t at
un	Calendar - March 2  Mon  05  Calendar - March 2	021 (Buy Tue 06	Back of Shar Wed 07 solidation of	08 • SIS Ltd Shares)		09		Sa 10 Sa 10	
UN CT UN	Calendar - March 2  Mon  05  Calendar - March 2  Mon	021 (Buy Tue 06 021 (Con Tu	Back of Shar Wed 07 solidation of te	08 • SIS Ltd Shares) Wed	Thu 08	09	Fri	Sa 10 Sa 10	
CT un	Calendar - March 2  Mon  05  Calendar - March 2  Mon  05  06	021 (Buy Tue 06 021 (Con Tu	Back of Shar Wed 07 solidation of te 0	08 • SIS Ltd Shares) Wed	Thu 08	09	Fri	Sa 10 Sa 10 td.	

April 05, 2021



## Religare Investment Calls

Religate investment calls								
Name of the Company	Reco Date	Current Rating*	Product Type	Reco Price	Target Price	Upside %	СМР	Expected returns from CMP %
Godrej Agrovet	13-Feb-2020	Buy	Investment Call	559	618	10.5%	518	19.3%
INOX Leisure	20-Aug-2020	Buy	High Conviction Ideas	282	376	33.3%	279	34.9%
Godrej Consumer Products	16-Sept-2020	Buy	Investment Call	706	845	19.7%	726	16.3%
Bharti Airtel	09-Nov-2020	Buy	High Conviction Ideas / Diwali Picks	450	709	57.6%	521	36.1%
Coromandel International	28-Dec-2020	Buy	New Year Picks 2021	802	978	21.9%	749	30.6%
Manappuram Finance	28-Dec-2020	Buy	New Year Picks 2021	164	205	25.0%	157	30.3%
Natco Pharma	28-Dec-2020	Buy	New Year Picks 2021	932	1,135	21.8%	842	34.8%
SBI Life Insurance	28-Dec-2020	Buy	New Year Picks 2021	874	1,069	22.3%	883	21.0%
Dabur India	04-Feb-2021	Buy	High Conviction Ideas	525	616	17.3%	539	14.4%
Castrol India	09-Feb-2021	Buy	Investment Call	134	148	10.4%	125	18.6%
Britannia Industries	10-Feb-2021	Buy	High Conviction Ideas	3,462	4,265	23.2%	3,619	17.9%
Mahindra and Mahindra	25-Feb-2021	Buy	High Conviction Ideas	850	1,087	27.9%	808	34.6%
Kansai Nerolac Paints	10-Маг-2021	Buy	High Conviction Ideas	589	705	19.7%	592	19.1%
Crompton Greaves Consumer Electricals	26-Mar-2021	Buy	High Conviction Ideas	367	479	30.5%	393	21.8%

\*Current rating is based on returns potential

Buy - Potential Returns >10% over 12 months

**Hold** - Potential Returns **<10%** over 12 months

For Religare Investment calls performance <u>click here</u>



# Current Portfolio and Performance Summary as on 01st April' 2021



Stock	Sector	Entry Date	Weight	Reco price (₹)	CMP (₹)
HDFC	Financial Services	August 14, 2018	8.9%	1,949	2,531
Maruti Suzuki India	Auto	August 28, 2018	5.0%	9,393	6,924
HDFC Bank	Financial Services	August 30, 2018	10.4%	1,037	1,487
Reliance Industries	Energy	December 20, 2018	12.4%	1,123	2,022
Godrej Consumer Products	Consumer Goods	May 27, 2019	6.2%	672	726
Axis Bank	Financial Services	Nov 6, 2019	7.9%	740	713
Aurobindo Pharma	Pharma	Nov 14, 2019	15.0%	396*	881
Hindalco Industries	Metals	Dec 05, 2019	13.8%	201	350
ACC	Cement	Jan 27, 2020	9.9%	1,575	1,913
	Cash		10.4%		
	Total		100%		


<sup>\*8.5%</sup> Aurobindo Pharma was bought at 819 and 4.7% was bought at 396



# Historical Performance as on 01<sup>st</sup> April' 2021



Performance Matrix	3-Month	6-Month	1-Year	Since Inception
Religare Alpha	6.7%	21.4%	80.4%	93.6%
Nifty	6.3%	30.2%	80.1%	88.6%
Outperformance	0.3%	-8.8%	0.3%	5.0%





#### **Research Product Basket**

- For every client, the advisor must allocate a specific proportion of funds for trading and investing depending on the risk taking ability and willingness of the client and their investment goals.
- The below mentioned product basket tries to address the way to deal with the trading portfolio (cash/derivative) for optimum effectiveness of research calls.
- It is recommended to divide your trading funds for various types of calls and not invest the entire amount for 1 or 2 calls only.

		For cash	market trading			For 1L m	argin*
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated		Total	Per Call
Intraday Calls	Intraday	2 - 3	< 1 day	25%		25,000	8,000
Live / RMD Calls	Daily	3 - 4	3 - 4 days	30%		30,000	4,000
Master Pick	Weekly	1	1 month	15%		15,000	5,000
Religare Alpha	Opportunity	NA	2 - 3 months	20%		20,000	As per weightage
Cash		NA		10%		10,000	
Intraday Calls				purpose of squaring off positions or nds should be allocated accordingly to			
Live / RMD Calls		lls). 3-4 such call	s are made on a daily basis v	days. Additionally as per market opp which might be open for 3-4 days. Fur			
Master Pick	_			f techno-funda analysis. 15% of fund: pen duration for this call will be 1 mor		nended to be a	llocated for Master
Religare Alpha	-		nich are held with a view of overall trading portfolio.	2-3 months. It is recommended to all	ocate 20%	of funds for bu	ilding this portfolio
Cash	10% surplus cash i	n the portfolio s	hould be kept for the purpo	oses of allocating it to opportunities a	s and wher	n they arrive.	

		For derivative n	narket trading		For 1L ma	argin*
Call / Product	Call Frequency	No. of calls	Avg open call duration	% funds allocated	Total	Per Call
Derivative Ideas	Daily	1 - 2	1 - 3 days	40%	40,000	40,000
Live calls	Intraday / Daily	1 - 2	3 - 4 days	50%	50,000	50,000
Cash		NA		10%	10,000	
Derivative Ideas			v. It can be a plain vanilla F&O be calls are open for 3-4 days on		egy. Funds should be allo	ocated assuming 2
Live Calls			ODIN during live market hours e open at any time. 3/4 times, th			s. Funds should be
Cash	It is recommended to	hold 10% cash to	capitalize on any opportunity th	nat may arise in markets.		

April 05, 2021



## **Research Analysts**

Ajit Mishra ajit.mishra@religare.com

Himanshu Sharma himanshu.sharma1@religare.com

Manoj M Vayalar manoj.vayalar@religare.com

**Nirvi Ashar** nirvi.ashar@religare.com

**Rohit Khatri** rohit.khatri@religare.com

**Suhanee Shome** suhanee.shome@religare.com

April 05, 2021



Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <a href="https://www.religareonline.com/disclaimer">https://www.religareonline.com/disclaimer</a>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA)

[Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) below, are given separately]

S. No.	Statement	An	swer
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one per cent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
-		1	1
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest ( if answer to F (a) above is Yes: .....

Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F (a) to F(j) above, are given below]

SSN	0.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No.

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results